Jakob S M, Frey F J, Uehlinger D E
Division of Nephrology, Department of Medicine, University of Berne, Inselspital, CH-3010 Berne, Switzerland.
Nephrol Dial Transplant. 1996 Jul;11(7):1250-5.
Continuous haemodialysis and continuous haemofiltration are efficient and safe techniques for the treatment of acute renal failure. Theoretical advantages are improved haemodynamic stability and easier fluid removal. All 15 available studies comparing intermittent (522 patients) with continuous (651 patients) renal replacement therapy have been reviewed. From these studies it cannot be established, whether the use of a continuous instead of an intermittent treatment modality improves the outcome in patients with acute renal failure. Reviewing all 67 published studies dealing with continuous renal replacement therapy revealed a trend to a decreasing mortality rate (P<0.08) over the last 11 years, whereas the mean age and the severity of illness of the patients, measured by the APACHE II score, did not change, In order to establish whether the quality of treatment has improved as a function of time, two quality factors (QF) were created, i.e. QF for age (mean age/mean mortality rate of the patients treated) and QF for severity of diseases (mean APACHE II/mean mortality rate). Both QF improved from 1984 until 1994, when analyzed for continuous (P<0.001) or intermittent (P<0.001) treatment modality. Thus the quality of treatment of patients with acute renal failure improved during the last decade. However, there is no evidence with respect to survival rate that a continuous renal replacement therapy is superior to an intermittent one.
连续性血液透析和连续性血液滤过是治疗急性肾衰竭的有效且安全的技术。理论优势在于改善血流动力学稳定性和更易于清除液体。我们回顾了所有15项比较间歇性(522例患者)和连续性(651例患者)肾脏替代治疗的现有研究。从这些研究中无法确定,对于急性肾衰竭患者,采用连续性而非间歇性治疗方式是否能改善预后。回顾所有67项关于连续性肾脏替代治疗的已发表研究发现,在过去11年中死亡率有下降趋势(P<0.08),而通过急性生理与慢性健康状况评分系统(APACHE II)衡量的患者平均年龄和疾病严重程度并未改变。为了确定治疗质量是否随时间有所改善,我们创建了两个质量因子(QF),即年龄质量因子(患者治疗平均年龄/平均死亡率)和疾病严重程度质量因子(平均APACHE II评分/平均死亡率)。对连续性(P<0.001)或间歇性(P<0.001)治疗方式进行分析时,这两个质量因子从1984年到1994年都有所改善。因此,在过去十年中急性肾衰竭患者的治疗质量有所提高。然而,就生存率而言,没有证据表明连续性肾脏替代治疗优于间歇性治疗。